<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866980</url>
  </required_header>
  <id_info>
    <org_study_id>AK105-301</org_study_id>
    <nct_id>NCT03866980</nct_id>
  </id_info>
  <brief_title>A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akeso Tiancheng, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III , randomized, double-blinded, multicenter clinical study to compare
      efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs
      Placebo combined with Carboplatin and Pemetrexed as first-line therapy in patients with EGFR
      and ALK wild type metastatic nonsquamous non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by IRRC or death due to any cause (whichever occurs first).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by IRRC or death due to any cause (whichever occurs first).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in ITT population</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is the time from the date of randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in PD-L1-selected population</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is the time from the date of randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by the investigator in accordance with RECIST v1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR is the proportion of subjects with CR or PR based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD based on RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From the time of informed consent signed through 90 days after last dose of AK105</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence or the deterioration of existing medical event in a clinical study subject administered an investigational drug, which does not necessarily have an unequivocal causal relationship with the investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentrations of AK105</measure>
    <time_frame>From first dose of AK105 through 90 days after last dose of AK105</time_frame>
    <description>The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK105 through 90 days after last dose of AK105</time_frame>
    <description>The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Lung Cancer Non-small Cell Stage IV</condition>
  <arm_group>
    <arm_group_label>AK105 plus Carboplatin and Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Carboplatin and Pemetrexed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK105</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK105 plus Carboplatin and Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK105 plus Carboplatin and Pemetrexed</arm_group_label>
    <arm_group_label>Placebo plus Carboplatin and Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>AK105 plus Carboplatin and Pemetrexed</arm_group_label>
    <arm_group_label>Placebo plus Carboplatin and Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo plus Carboplatin and Pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent form voluntarily.

          -  Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when
             signing the ICF.

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

          -  Expected life expectance â‰¥ 3 months.

          -  Histologically or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.

          -  No prior systemic chemotherapy for advanced or metastatic NSCLC. Subjects who have
             received prior adjuvant chemotherapy or neoadjuvant chemotherapy with curative intent,
             or definitive chemoradiotherapy for advanced disease, will be eligible provided that
             progression has occurred &gt;6 months from last treatment.

          -  At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously
             irradiated will not be considered a target lesion.

          -  Subjects must provide an available tumor tissue sample taken &lt; 6 months prior to first
             dose of study treatment.

          -  Subjects must provide wild-type EGFR and ALK reported by tissue-based tests. For
             subjects without documented wild-type EGFR/ALK, archival or fresh tumor tissues are
             required for EGFR/ALK assessment prior to enrollment.

          -  Adequate organ function.

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use at least one highly effective method of contraception.

          -  Nonsterilized males who are sexually active with a female partner of childbearing
             potential must use highly effective method of contraception from Day 1 and for 120
             days after the last dose of investigational product.

        Exclusion Criteria:

          -  Subjects who are diagnosed as NSCLC that harbors an EGFR-sensitizing mutation or ALK
             gene translocation.

          -  Subjects with other histological types of NSCLC, including mixed squamous cell
             carcinoma and adenocarcinoma, and mixed carcinoma containing small cell lung carcinoma
             or neuroendocrine carcinoma.

          -  Received prior treatment with EGFR inhibitors or ALK inhibitors.

          -  Receipt of last radiotherapy or any anti-tumor treatment [chemotherapy, targeted
             therapy, immunotherapy, Chinese patent drugs with antitumor indications, or
             immunomodulators or tumor embolization] within 3 weeks prior to the first dose of
             study treatment.

          -  Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other
             antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as
             ICOS or agonists (e.g. CD40, CD137, GITR and OX40 etc).

          -  Other invasive malignancies within 5 years, except for locally treatable (manifested
             as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial
             bladder cancer, cervical or breast carcinoma in situ.

          -  Subjects with active, known or suspected autoimmune disease, or a medical history of
             autoimmune disease, with the exceptions of the following: vitiligo, alopecia, Grave
             disease, psoriasis or eczema not requiring systemic treatment within the last 2 years,
             hypothyroidism (caused by autoimmune thyroiditis) only requiring steady doses of
             hormone replacement therapy and type I diabetes only requiring steady doses of insulin
             replacement therapy, or completely relieved childhood asthma that requires no
             intervention in adulthood, or primary diseases that will not relapse unless triggered
             by external factors.

          -  Active or previously documented inflammatory bowel disease (e.g. Crohn's disease,
             ulcerative colitis or chronic diarrhea).

          -  Subjects who require systemic corticosteroids (a dose equivalent to &gt;10 mg/day
             prednisone) or other immunosuppressive drugs within 14 days prior to the first dose of
             study drug.

          -  Major surgery (as defined by the investigator) within 28 days prior to the first dose
             of study drug.

          -  Subjects who received non-thoracic radiotherapy &gt;30 Gy within 4 weeks prior to the
             first dose, or thoracic radiotherapy &gt;30 Gy within 24 weeks prior to the first dose
             study drug.

          -  History of gastrointestinal perforation and/ or fistula within 6 months prior to the
             first dose of study drug.

          -  Known history of primary immunodeficiency virus infection.

          -  Known history of allogeneic organ transplantation or allogeneic hematopoietic stem
             cell transplantation.

          -  Known history of interstitial lung disease.

          -  Known history of active tuberculosis (TB).

          -  Serious infections within 4 weeks prior to the first dose of study drug, including but
             not limited to complications requiring hospitalization, sepsis or severe pneumonia.

          -  An active infection requiring systemic therapy.

          -  Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA
             exceeding 500 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects
             with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA &lt;500 IU/ mL) ,
             and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are
             eligible only if the HCV RNA test results are negative.

          -  Known history of testing positive for human immunodeficiency virus (HIV).

          -  Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease or
             active brain metastasis.

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage.

          -  Clinically active hemoptysis, active diverticulitis, peritoneal abscess, or
             gastrointestinal obstruction.

          -  Clinically significant bleeding symptoms or significant bleeding tendency such as
             gastrointestinal bleeding, hemorrhagic gastric ulcer or vasculitis within 1 month
             prior to the first dose of study treatment.

          -  Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
             NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion
             criteria, with the exception of alopecia.

          -  Receipt of live or attenuated vaccination within 30 days prior to the first dose of
             study treatment, or plan to receive live or attenuated vaccine during the study.

          -  Known history of server hypersensitivity to other monoclonal antibodies.

          -  Known severe allergic reactions to pemetrexed, carboplatin or platinum-containing
             component, or their preventive medications.

          -  Known allergic reactions to any ingredients of AK105.

          -  Pregnant or lactating women.

          -  Any conditions that, in the investigator's opinion, may put subjects treated with the
             study drug at risks, or interfere with the evaluation of study drug or subject safety,
             or the interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shunchang Jiao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baohui Han, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoping Jin</last_name>
    <phone>86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangfang Jing, MD</last_name>
      <phone>86-010-66937003</phone>
    </contact>
    <investigator>
      <last_name>Shunchang Jiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Baohui Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy,immuno-oncology, non-small cell lung cancer</keyword>
  <keyword>Anti-PD-1 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

